Drug intelligence / Profile preview

recombinant lymphoma idiotype vaccine

Development stage: Unknown
Lead developer: Universitätsklinikum Freiburg
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intradermal

Overview

The recombinant lymphoma idiotype vaccine is an individualized **therapeutic cancer vaccine** developed at University Medical Center Freiburg for indolent B-cell lymphomas. Each patient-specific product contains recombinant Fab fragments representing the variable-region idiotype of the malignant B-cell clone's surface immunoglobulin, produced in *Escherichia coli*. Intradermal vaccination with adjuvanted recombinant Fab protein is intended to induce idiotype-specific humoral and T-cell immune responses against lymphoma cells; granulocyte-macrophage colony-stimulating factor was co-administered subcutaneously as an immune adjuvant in clinical studies. The program was evaluated in Phase I advanced B-cell lymphoma and Phase II indolent B-cell lymphoma studies, including follicular lymphoma.

Other names: Fab IdIdvaxIIrecombinant idiotype Fab fragment vaccine

Targets

Id (Tumor-specific idiotype immunoglobulin)

Beyond the preview

Go deeper on recombinant lymphoma idiotype vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant lymphoma idiotype vaccine.

Explore the full profile